Back to Report Store Home

Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

  • Published: Oct-2017
  • Report Code: GBIHC456MR
  • Report Format: pdf

Description

List of Figures

Figure 1: T2DM Therapeutics Market, Comparative Efficacy and Safety Heatmap for Conventional Anti-diabetic Marketed Products 79

Figure 2: T2DM Therapeutics Market, Comparative Efficacy and Safety Heatmap for GLP-1 Receptor 80

Figure 3: T2DM Therapeutics Market, Comparative Efficacy and Safety Heatmap for DPP-4 inhibitors 81

Figure 4: T2DM Therapeutics Market, Comparative Efficacy and Safety Heatmap for SGLT-2 Inhibitors 82

Figure 5: T2DM Therapeutics Market, Comparative Efficacy and Safety Heatmap for Insulin Therapy 83

Figure 6: T2DM Therapeutics Market, Global, Pipeline, 2017 86

Figure 7: T2DM Therapeutics Market, Global, Pipeline by Molecular Target, 2017 90

Figure 8: T2DM Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2017 91

Figure 9: T2DM Therapeutics Market, South-East Asia, NN-9535 Forecast ($m), 2018–2023 94

Figure 10: T2DM Therapeutics Market, South-East Asia, OG-217SC Forecast ($m), 2020–2023 94

Figure 11: T2DM Therapeutics Market, South-East Asia, Ertugliflozin Forecast ($m), 2018–2023 96

Figure 12: T2DM Therapeutics Market, South-East Asia, Bexagliflozin Forecast ($m), 2020–2023 97

Figure 13: T2DM Therapeutics Market, South-East Asia, Omarigliptin Forecast ($m), 2017–2023 99

Figure 14: T2DM Therapeutics Market, South-East Asia, Sotagliflozin Forecast ($m), 2021–2023 100

Figure 15: T2DM Therapeutics Market, South-East Asia, Heatmap for Pipeline Products, April 2017 102

Figure 16: T2DM Therapeutics Market, South-East Asia, Competitor Matrix for Marketed and Pipeline Products, April 2017 104

Figure 17: T2DM Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006–2017 106

Figure 18: T2DM Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type, 2006–2017 107

Figure 19: T2DM Therapeutics, Global, Clinical Trial Failure Rate by Molecular Target, 2006–2017 108

Figure 20: T2DM Therapeutics, Global, Clinical Trial Duration by Phase and Molecule Type, 2006–2017 109

Figure 21: T2DM Therapeutics, Global, Clinical Trial Duration by Phase and Molecular Target, 2006–2017 110

Figure 22: T2DM Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006–2017 111

Figure 23: T2DM Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecular Target, 2006–2017 112

Figure 24: T2DM Therapeutics, Global, Clinical Trial Size per Individual Trial by Molecule Type (participants), 2006–2017 113

Figure 25: T2DM Therapeutics, Global, Clinical Trial Size per Individual Trial by Molecular Target (participants), 2006–2017 114

Figure 26: T2DM Therapeutics, Global, Comparison of Average Trial Metrics by Phase and Molecular Type 115

Figure 27: T2DM Therapeutics, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 115

Figure 28: T2DM Therapeutics Market, South-East Asia, Treatment Usage Patterns (million), 2016–2023 117

Figure 29: T2DM Therapeutics Market, South-East Asia, Market Size ($bn), 2016–2023 118

Figure 30: T2DM Therapeutics Market, South Korea, Treatment Usage Patterns (million), 2016–2023 119

Figure 31: T2DM Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016–2023 120

Figure 32: T2DM Therapeutics Market, South Korea, Market Size ($m), 2016–2023 121

Figure 33: T2DM Therapeutics Market, Singapore, Treatment Usage Patterns (million), 2016–2023 122

Figure 34: T2DM Therapeutics Market, Singapore, Annual Cost of Therapy ($), 2016–2023 122

Figure 35: T2DM Therapeutics Market, Singapore, Market Size ($m), 2016–2023 123

Figure 36: T2DM Therapeutics Market, Taiwan, Treatment Usage Patterns (million), 2016–2023 124

Figure 37: T2DM Therapeutics Market, Taiwan, Annual Cost of Therapy ($), 2016–2023 124

Figure 38: T2DM Therapeutics Market, Taiwan, Market Size ($m), 2016–2023 125

Figure 39: T2DM Therapeutics Market, Malaysia, Treatment Usage Patterns (million), 2016–2023 126

Figure 40: T2DM Therapeutics Market, Malaysia, Annual Cost of Therapy ($), 2016–2023 126

Figure 41: T2DM Therapeutics Market, Malaysia, Market Size ($m), 2016–2023 127

Figure 42: T2DM Therapeutics Market, Philippines, Treatment Usage Patterns (million), 2016–2023 128

Figure 43: T2DM Therapeutics Market, Philippines, Annual Cost of Therapy ($), 2016–2023 129

Figure 44: T2DM Therapeutics Market, Philippines, Market Size ($m), 2016–2023 130

Figure 45: T2DM Therapeutics Market, Thailand, Treatment Usage Patterns (million), 2016–2023 131

Figure 46: T2DM Therapeutics Market, Thailand, Annual Cost of Therapy ($), 2016–2023 131

Figure 47: T2DM Therapeutics Market, Thailand, Market Size ($m), 2016–2023 132

Figure 48: T2DM Therapeutics Market, Vietnam, Treatment Usage Patterns (million), 2016–2023 133

Figure 49: T2DM Therapeutics Market, Vietnam, Annual Cost of Therapy ($), 2016–2023 134

Figure 50: T2DM Therapeutics Market, Vietnam, Market Size ($m), 2016–2023 135

Figure 51: T2DM Therapeutics Market, Indonesia, Treatment Usage Patterns (million), 2016–2023 136

Figure 52: T2DM Therapeutics Market, Indonesia, Annual Cost of Therapy ($), 2016–2023 136

Figure 53: T2DM Therapeutics Market, Indonesia, Market Size ($m), 2016–2023 137

Figure 54: T2DM Therapeutics, Global, Licensing Deals by Region and Value, 2006– April 2017 141

Figure 55: T2DM Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006– April 2017 142

Figure 56: T2DM Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006–April 2017 143

Figure 57: T2DM Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006– April 2017 144

Figure 58: T2DM Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006–April 2017 145

Figure 59: T2DM Therapeutics Market, Global, Co-development Deals by Value ($m), 2006–April 2017 149

Figure 60: T2DM Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006– April 2017 150

Figure 61: T2DM Therapeutics Market, Global, Co-development Deals by Deal Value ($m), Upfront Payment Value ($m) and Stage of Development, 2006–April 2017 151

Figure 62: T2DM Therapeutics Market, Global, Co-development Deals by Stage of Development, Molecule Type and Aggregate Deal Value ($bn), 2006–April 2017 152

Figure 63: T2DM Therapeutics Market, Global, Co-development Deals by Molecular Target and Aggregate Deal Value ($m), 2006–April 2017 153

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards